CLINICAL TRIALS PROFILE FOR APLENZIN
✉ Email this page to a colleague
All Clinical Trials for APLENZIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00991081 ↗ | Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. | Completed | Johns Hopkins University | Phase 4 | 2009-07-01 | The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy. |
| NCT00991081 ↗ | Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. | Completed | National Institute on Drug Abuse (NIDA) | Phase 4 | 2009-07-01 | The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy. |
| NCT00991081 ↗ | Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. | Completed | SRI International | Phase 4 | 2009-07-01 | The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy. |
| NCT00991081 ↗ | Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. | Completed | University of Bristol | Phase 4 | 2009-07-01 | The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy. |
| NCT00991081 ↗ | Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. | Completed | Stanford University | Phase 4 | 2009-07-01 | The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy. |
| NCT02129751 ↗ | Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder | Not yet recruiting | Bausch Health Americas, Inc. | Phase 4 | 2021-11-01 | Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety |
| NCT02129751 ↗ | Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder | Not yet recruiting | Valeant Pharmaceuticals International, Inc. | Phase 4 | 2021-11-01 | Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for APLENZIN
Condition Name
Clinical Trial Locations for APLENZIN
Trials by Country
Clinical Trial Progress for APLENZIN
Clinical Trial Phase
Clinical Trial Sponsors for APLENZIN
Sponsor Name
